Format

Send to

Choose Destination
Diabetologia. 2017 Sep;60(9):1594-1600. doi: 10.1007/s00125-017-4364-6. Epub 2017 Aug 2.

A new perspective on metformin therapy in type 1 diabetes.

Author information

1
Institute of Cardiovascular and Medical Sciences, BHF Glasgow Cardiovascular Research Centre, University of Glasgow, 126 University Place, Glasgow, G12 8TA, UK.
2
Glasgow Royal Infirmary, Glasgow, UK.
3
School of Medicine, University of Glasgow, Glasgow, UK.
4
Institute of Cardiovascular and Medical Sciences, BHF Glasgow Cardiovascular Research Centre, University of Glasgow, 126 University Place, Glasgow, G12 8TA, UK. john.petrie@glasgow.ac.uk.

Abstract

Metformin is quite frequently used off-label in type 1 diabetes to limit insulin dose requirement. Guidelines recommend that it can improve glucose control in those who are overweight and obese but evidence in support of this is limited. Recently-published findings from the REducing with MetfOrmin Vascular Adverse Lesions (REMOVAL) trial suggest that metformin therapy in type 1 diabetes can reduce atherosclerosis progression, weight and LDL-cholesterol levels. This provides a new perspective on metformin therapy in type 1 diabetes and suggests a potential role for reducing the long-term risk of cardiovascular disease.

KEYWORDS:

Atherosclerosis; Cardiovascular; Carotid intima-media thickness; Cholesterol; Metformin; Review; Type 1 diabetes

PMID:
28770327
PMCID:
PMC5552844
DOI:
10.1007/s00125-017-4364-6
[Indexed for MEDLINE]
Free PMC Article

Supplemental Content

Full text links

Icon for Springer Icon for PubMed Central
Loading ...
Support Center